Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanologica AB ( (SE:NICA) ) has provided an update.
Nanologica AB has secured an order worth approximately SEK 1 million for its silica-based purification media, NLAB Saga®, from a new distribution partner in China. This order marks a significant step in expanding their market presence in China, as the company aims to increase sales efforts and serve more customers efficiently. The order is expected to be delivered in the fourth quarter, highlighting the company’s stable production and strategic focus on the Chinese market.
The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Their products are designed for the purification of peptide drugs, such as insulin and GLP-1 analogues, aiming to increase productivity and reduce costs for pharmaceutical manufacturers. The company operates in a growing global niche market driven by the demand for diabetes and obesity treatments, and is listed on Nasdaq Stockholm Main Market.
Average Trading Volume: 131,350
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK112.7M
Find detailed analytics on NICA stock on TipRanks’ Stock Analysis page.